Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections

July 2011
American Journal of Health-System Pharmacy;7/1/2011, Vol. 68 Issue 13, p1207
Academic Journal
Purpose. Recent in vitro and clinical data addressing outstanding issues regarding the selection, dosing, and monitoring of echinocandins for the treatment of invasive fungal infections (IFIs) are reviewed. Summary. The echinocandins (caspofungin, micafungin, and anidulafungin) are attractive treatment options for the treatment of select IFIs, most notably invasive candidiasis and treatment-refractory invasive aspergillosis. A literature review of English-language articles published between January 2007 and May 2010 was performed using the terms caspofungin, micafungin, anidulafungin, and echinocandin. In vitro, in vivo, and both pediatric and adult clinical studies and case reports were included. The challenges to establish meaningful interpretive criteria for in vitro testing of yeasts continue to persist, as do the establishment of the clinical relevancy of both the reduced in vitro susceptibilities to Candida parapsilosis and the paradoxical growth of Candida species at higher dosages. Despite increasing use of these agents and reports of breakthrough infections, echinocandins have continued to maintain potency against a broad spectrum of Candida and Aspergillus species. Recent in vitro studies also support the excellent activity of echinocandins against Candida biofilms. While recent published studies have better defined dosing in special populations (such as pediatric patients and those with organ dysfunction), attempts to increase efficacy by dosage intensification have been unsuccessful. Several pharmacoeconomic studies have been performed in attempts to justify the high acquisition costs of these drugs. In general, these studies found that echinocandins may be cost-effective for such indications. Conclusion. Available in vitro data, animal studies, and clinical studies do not clearly differentiate agents in the echinocandin class. Clinical data continue to support the use of echinocandins as a safe and well-tolerated treatment option for candidemia and invasive aspergillosis.


Related Articles

  • The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins. Hinske, Ludwig Christian G.; Weis, Florian; Heyn, Jens; Hinske, Patricia; Beiras-Fernandez, Andres // Recent Patents on Anti-Infective Drug Discovery;Apr2012, Vol. 7 Issue 1, p1 

    Fungal infections are becoming an increasing menace in the hospital care setting. Among them, non-albicans Candida species have gained significant attention. Especially in the ICU setting, therapeutic options are limited in many cases by the side-effects of conventional antifungal therapy....

  • Echinocandin pharmacodynamics: review and clinical implications. Pound, Melanie W.; Townsend, Mary L.; Drew, Richard H. // Journal of Antimicrobial Chemotherapy (JAC);Jun2010, Vol. 65 Issue 6, p1108 

    Echinocandins have made a significant impact in the treatment of select invasive fungal infections, most notably invasive candidiasis and aspergillosis. However, treatment outcomes for such infections are still less than optimal, prompting an examination of dosing and administration techniques...

  • Delayed-release Posaconazole Tablets Offer Increased Exposure in a Fasted State. Lindsay, Caroline A. // Infectious Disease Alert;Apr2014, Vol. 33 Issue 7, p76 

    The article focuses on Posaconazole delayed-released tablets that was recently approved for prophylaxis of invasive Aspergillus and Candida infections in immunocompromised patients at least 13 years of age. It notes that these new delayed-release tablets produce superior drug exposure than the...

  • Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review. Lass-Florl, Cornelia // Drugs;2011, Vol. 71 Issue 18, p2405 

    Invasive fungal disease continues to be a problem associated with significant morbidity and high mortality in immunocompromised and, to a lesser extent, immunocompetent individuals. Triazole antifungals have emerged as front-line drugs for the treatment and prophylaxis of many systemic mycoses....

  • Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis. Denning, David W.; Ribaud, Patricia; Milpied, Noel; CAillot, Denis; Herbrecht, Raoul; Thiel, Eckhard; Haas, Andrea; Ruhnke, Markus; Lode, Hartmut // Clinical Infectious Diseases;3/1/2002, Vol. 34 Issue 5, p563 

    Evaluates the clinical efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis (IA) in neutropenic and other immunocompromised patients. Clinical features and sites of IA; Clinical outcome of treatment; Factors that influenced the outcome.

  • Posaconazole.  // Reactions Weekly;8/7/2010, Issue 1313, p35 

    The article describes the case of a 19-year-old man with acute myeloid leukaemia who developed aspergillosis despite prophylactic treatment with posaconazole .

  • Fluconazole.  // Reactions Weekly;9/18/2010, Issue 1319, p24 

    The article describes the case of a 64-year-old woman who presented with a 3-day history of several well-demarcated, erythematous ovoid patches on her arms, palms and lower leg after receiving treatment with oral fluconazole for vaginal candidiasis.

  • Hepatic Candidiasis in Cancer Patients: The Evolving Picture of the Syndrome. Thaler, Michael; Pastakia, Behram; Shawker, Thomas H.; O'Leary, Timothy; Pizzo, Philip A. // Annals of Internal Medicine;Jan88, Vol. 108 Issue 1, p88 

    Presents a study which examined the evolving nature of hepatosplenic candidiasis, focusing on diagnosis and treatment. Characteristics of focal hepatosplenic; Use of intensive chemotherapy; Reason for recommending the use of empirical anti-fungal therapy for high-risk patients; Description of...

  • Prophylactic Antifungal Therapy in the Intensive Care Unit. Rex, John H.; Sobel, Jack D. // Clinical Infectious Diseases;4/15/2001, Vol. 32 Issue 8, p1191 

    Examines the effectiveness of the use of antifungal prophylaxis in the prevention of candidal infections among intensive care unit (ICU) patients who do not have neutropenia. Factors which may contribute to the possibility of the use of prophylaxis; Relevance of prophylaxis to the population of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics